To study the effect of Dantyadi Lepa and Swarjika Ksharadi Lepa in Stana-granthi with special reference to Fibroadenosis

Comparative study of Dantyadi Lepa and Swarjika Ksharadi Lepa in Stana-granthi with special reference to Fibroadenosis - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058860

Enrollment

Registered

2023-10-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N602- Fibroadenosis of breast

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with benign disease of breast- presenting as breast lump, breast pain or nipple discharge in either of the breast or both breasts Diagnosed cases of Fibroadenosis by USG/USG mammography

Exclusion criteria

Exclusion criteria: Patient with a discrete breast lump that is suspicious of malignancy Skin allergy (particularly over the breast) Open wound Neoplasm Patients did not give consent to participate in the study Who are not willing for follow-up

Design outcomes

Primary

Measure	Time frame
?To evaluate the general patho- physiology of Stana-granthi in both Ayurveda and Modern sciences. To evaluate the clinical efficacy of local application of Dantyadi Lepa and Swarjika Ksharadi Lepa in Stana granthi with special reference to Fibroadenosis To compare the therapeutic efficacy of both the lepas To standardize both the lepas as per Pharmaceutical and Analytical parametersTimepoint: Total 2 months trials with 4 follow-ups in every 15 days of gap	—

Measure

Time frame

?To evaluate the general patho- physiology of Stana-granthi in both Ayurveda and Modern sciences. To evaluate the clinical efficacy of local application of Dantyadi Lepa and Swarjika Ksharadi Lepa in Stana granthi with special reference to Fibroadenosis To compare the therapeutic efficacy of both the lepas To standardize both the lepas as per Pharmaceutical and Analytical parametersTimepoint: Total 2 months trials with 4 follow-ups in every 15 days of gap

—

Secondary

Measure	Time frame
To compare the therapeutic efficacy of both the lepas To standardize both the lepasTimepoint: 2months	—

Countries

India

Contacts

Public ContactDr Anuradha Roy

Banaras Hindu University

dranuradha369@gmail.com9956630433

Outcome results